This is a Phase I, combination of single ascending dose/multiple ascending dose to evaluate the safety and pharmacokinetics of birinapant as a single agent in patients infected with chronic Hepatitis B virus.

Trial Profile

This is a Phase I, combination of single ascending dose/multiple ascending dose to evaluate the safety and pharmacokinetics of birinapant as a single agent in patients infected with chronic Hepatitis B virus.

Planning
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2015

At a glance

  • Drugs Birinapant (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors TetraLogic Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2015 According to the media release of TetraLogic pharmaceuticals, this study is expect to initiate at multiple sites in India in early 2016 and the timing of results will depend upon enrollment rates.
    • 07 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top